The Enterprise Value as of September 2024 (TTM) for Innovent Biologics, Inc. (IVBXF) is 9.98B

According to Innovent Biologics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.98B. This represents a change of -73.96% compared to the average of 38.30B of the last 4 quarters.

Innovent Biologics, Inc. (IVBXF) Historical Enterprise Value (quarterly & annually)

How has IVBXF Enterprise Value performed in the past?

The mean historical Enterprise Value of Innovent Biologics, Inc. over the last ten years is 40.88B. The current 9.98B Enterprise Value has changed 2.34% with respect to the historical average. Over the past ten years (40 quarters), IVBXF's Enterprise Value was at its highest in in the June 2021 quarter at 108.82B. The Enterprise Value was at its lowest in in the March 2021 quarter at -9322770000.00.

Innovent Biologics, Inc. (IVBXF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Innovent Biologics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innovent Biologics, Inc. (IVBXF) Average Enterprise Value

How has IVBXF Enterprise Value performed in the past?

The current Enterprise Value of Innovent Biologics, Inc. (IVBXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Innovent Biologics, Inc. (IVBXF) Enterprise Value vs. Peers

How is IVBXF’s Enterprise Value compared to its peers?

Innovent Biologics, Inc.’s Enterprise Value is greater than Telix Pharmaceuticals Limited (5.79B), greater than Keros Therapeutics, Inc. (1.74B), greater than MAIA Biotechnology, Inc. (58.59M), greater than Graphite Bio, Inc. (-15007658.00), less than Genscript Biotech Corporation (0), greater than Oxford Nanopore Technologies plc (3.00B), greater than Nuvalent, Inc. (1.42B), greater than Crinetics Pharmaceuticals, Inc. (7.37B), greater than Inhibrx, Inc. (4.14B), greater than Merus N.V. (26.18M), greater than Lyell Immunopharma, Inc. (2.85B), greater than Kronos Bio, Inc. (326.03M), greater than Theseus Pharmaceuticals, Inc. (14.20M), greater than Cullinan Oncology, Inc. (138.26M), greater than Mersana Therapeutics, Inc. (906.65M), greater than Relay Therapeutics, Inc. (245.65M), greater than Arcus Biosciences, Inc. (1.21B), greater than null (1.42B),

Build a custom stock screener for Innovent Biologics, Inc. (IVBXF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innovent Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innovent Biologics, Inc. (IVBXF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innovent Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.